Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Atticus Wealth Management LLC

Atticus Wealth Management LLC raised its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 833.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 140 shares of the pharmaceutical company’s stock after acquiring an additional 125 shares during the period. Atticus Wealth Management LLC’s holdings in Vertex Pharmaceuticals were worth $56,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. Mutual Advisors LLC lifted its position in shares of Vertex Pharmaceuticals by 0.6% during the 3rd quarter. Mutual Advisors LLC now owns 3,710 shares of the pharmaceutical company’s stock worth $1,751,000 after purchasing an additional 21 shares during the last quarter. Daymark Wealth Partners LLC increased its holdings in shares of Vertex Pharmaceuticals by 2.8% in the 3rd quarter. Daymark Wealth Partners LLC now owns 804 shares of the pharmaceutical company’s stock valued at $374,000 after acquiring an additional 22 shares during the last quarter. Grove Bank & Trust lifted its position in shares of Vertex Pharmaceuticals by 5.7% during the 3rd quarter. Grove Bank & Trust now owns 410 shares of the pharmaceutical company’s stock worth $191,000 after buying an additional 22 shares during the last quarter. Outlook Wealth Advisors LLC grew its position in shares of Vertex Pharmaceuticals by 2.8% in the 3rd quarter. Outlook Wealth Advisors LLC now owns 892 shares of the pharmaceutical company’s stock valued at $415,000 after buying an additional 24 shares during the last quarter. Finally, Dunhill Financial LLC raised its stake in Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 24 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on VRTX shares. Wells Fargo & Company decreased their price objective on Vertex Pharmaceuticals from $555.00 to $460.00 and set an “overweight” rating for the company in a report on Friday, January 10th. Morgan Stanley increased their price objective on Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. William Blair restated an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Monday, January 13th. Raymond James reissued a “market perform” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, October 10th. Finally, Jefferies Financial Group raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price target for the company from $500.00 to $550.00 in a report on Monday, December 9th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $494.84.

Vertex Pharmaceuticals Trading Down 0.0 %

Vertex Pharmaceuticals stock opened at $439.62 on Monday. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The business has a 50 day moving average price of $435.36 and a two-hundred day moving average price of $464.51. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.77. The business had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm’s revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the business earned $3.67 EPS. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.